Trial Search Results

Prospective Evaluation of the Biobridge Scaffold as an Adjunct to Lymph Node Transfer for Upper Extremity Lymphedema

To investigate whether addition of the Biobridge scaffold to the standard surgery for vascularized lymph node transfer will improve the outcome of surgical treatment in lymphedema of the upper arm.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):

Intervention(s):

  • Device: Biobridge and lymph node transfer

Phase:

N/A

Eligibility


Inclusion Criteria:

The diagnosis of obstructive lymphedema typically relies upon the clinical presentation and
physical findings. All of the subjects will be required to present a compatible history of
acquired lymphedema, along with the following criteria: sustained, unilateral,
conservatively-managed edema of the upper limb, with an increase of at least 20% in the
measured volume of the affected extremity when compared with the contralateral, normal
limb. In addition, the subject must have evidence of an abnormal bioimpedance ratio (L-Dex
> 10 units). The subject must submit evidence of previous, completed complex decongestive
physiotherapy and the ongoing use of an appropriately sized compression garment for daytime
use. Ancillary use of nocturnal garments and/or pneumatic compression devices is
acceptable, but not necessary. The subject must be eligible for surgical intervention.

   - Swelling of 1 arm that is not completely reversed by arm elevation or compression

   - Stage II or greater lymphedema at screening, based on the International Society of
   Lymphology (ISL) staging system

   - Completion of a full course of complete decongestive therapy (CDT), according to ISL
   guidelines at least 8 weeks prior to screening, including use of compression garments
   for at least 8 weeks without change in regimen

   - Willingness to maintain a stable regimen of self-care, including use of compression
   garments from screening through the entire study duration (through the safety
   follow-up visit). Self-bandaging, use of nighttime compression garments, and
   intermittent pneumatic compression devices are allowed, but the procedures and
   regimens must remain consistent from screening though the entire study duration.

   - Two consecutive measurements of limb volume (LV) in the affected arm taken at least 1
   day apart during the screening period must be within 10% of each other. A maximum of 3
   measurements can be taken.

   - Willing and able to provide written informed consent

   - Willing and able to comply with all study procedures, including measurement of skin
   thickness using skin calipers

Exclusion Criteria:

   - inability to safely undergo general anesthesia and/or perioperative care related to
   vascularized lymph node transfer

   - Concurrent participation in a clinical trial of any other investigational drug or
   therapy, regardless of indication, within

   1 month before screening or 5 times the drug's half-life, whichever is longer

   - Recent initiation of (≤8 weeks), or intention to initiate, CDPT or maintenance
   physiotherapy for lymphedema at any time during the duration of the study

   - Other medical condition that could lead to acute arm edema, such as (but not limited)
   to acute venous thrombosis

   - Other medical condition that could result in symptoms overlapping those of lymphedema
   in the affected arm (e.g.,pain, swelling, decreased range of motion)

   - History of clotting disorder (hypercoagulable state)

   - Chronic (persistent) infection in the affected arm

   - Any other infection (unrelated to lymphedema) within 1 month prior to screening

   - Current evidence of malignancy

   - Currently receiving chemotherapy or radiation therapy

   - Life expectancy < 2 years for any reason

   - Pregnancy or nursing

   - Substance abuse (such as alcohol or drug abuse) within 6 months prior to screening

   - Significant or chronic renal insufficiency (defined as serum creatinine >2.5 mg/dL or
   an estimated glomerular filtration rate [eGFR] <30 mL/min at screening) or requires
   dialytic support

   - Hepatic dysfunction, defined as alanine transaminase (ALT) or aspartate transaminase
   (AST) levels >3 × upper limit of the normal range (ULN) and/or bilirubin level >2 ×
   ULN at screening

   - Absolute neutrophil count <1500 mm3 at screening

   - Hemoglobin concentration <9 g/dL at screening

   - Any reason (in addition to those listed above) that, in the opinion of the
   investigator, precludes full participation in the study

Ages Eligible for Study

18 Years - 75 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Recruiting